Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
3 Investable Laggards In An Overbought Market
05:13pm, Tuesday, 28'th Oct 2025
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo
5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade
02:15pm, Tuesday, 28'th Oct 2025
There's no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment.
Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks
01:20pm, Tuesday, 28'th Oct 2025
Following in the footsteps of David Solomon at Goldman Sachs and Jamie Dimon at JPMorgan, Ark Investments guru Cathie Wood recently warned of the potential for a reality check for the stock market aft
3 Dividend-Paying Drug Stocks to Buy at a Discount
02:00pm, Monday, 27'th Oct 2025
Pfizer currently has a 7% yield, and the company is making important business moves. Bristol Myers Squibb has a 5.6% yield and has been building its drug pipeline with acquisitions.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
12:06pm, Monday, 27'th Oct 2025
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
10:21am, Monday, 27'th Oct 2025
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:16am, Monday, 27'th Oct 2025
Besides Wall Street's top-and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during th
Bristol-Myers Squibb: Earnings Champion Valued Like A Loser
09:13am, Monday, 27'th Oct 2025
Bristol-Myers Squibb Company has a strong track record of beating analyst estimates, yet trades at a deeply pessimistic valuation. BMY's Q3 earnings are highly likely to beat consensus, reinforcing co
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR25--BMS Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus.
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
02:50am, Monday, 27'th Oct 2025
Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR25--BMS Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR.
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
12:30pm, Friday, 24'th Oct 2025
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space.
Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs
07:54am, Friday, 24'th Oct 2025
Nine of fifteen Barron's Better Bets (BBB) 'safer' high-yield dividend stocks are currently attractively priced, including CAG, VZ, MO, BMY, TFC, UDR, KEY, KIM, and RF. Analyst forecasts project top-t
Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare
05:20pm, Thursday, 23'rd Oct 2025
Bristol-Myers Squibb is deeply undervalued despite a 23% YTD stock decline, offering compelling value in the healthcare sector. BMY faces significant patent expirations but is proactively mitigating r
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
11:07am, Thursday, 23'rd Oct 2025
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
